Tags

Type your tag names separated by a space and hit enter

Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for anti-HBc antibody in Japan.
Am J Gastroenterol. 2002 Jan; 97(1):156-61.AJ

Abstract

OBJECTIVE

We determined the prevalence of patients with hepatocellular carcinoma (HCC) who were positive for only anti-hepatitis B core (anti-HBc) antibody among 284 Japanese patients and compared their clinical features to those who were hepatitis B surface antigen positive [HBsAg(+)].

METHODS

Serum HBsAg and anti-hepatitis C virus (anti-HCV) antibody were examined for all HCC patients. Testing for anti-HBc antibody was performed in the HBsAg(-)/anti-HCV(-) patients. The clinical factors and the survival rate were compared between the HBsAg(+) patients (HCC-B) and those positive for anti-HBc alone (HCC-PB).

RESULTS

There were 19 (6.7%) HBsAg(+), 236 (83.1%) anti-HCV(+), seven (2.5%) HBsAg(+)/anti-HCV(+), and 22 (7.7%) HBsAg(-)/anti-HCV(-) among the 284 patients tested. Sixteen (72.7%) of the 22 HBsAg(-)/anti-HCV(-) patients were assigned to the HCC-PB group. The prevalence of positivity for anti-HBc alone among all 284 HCC patients was 5.6%. Significant differences between the HCC-PB and HCC-B groups were that age at diagnosis was higher in the HCC-PB group (72.1 yr) than in the HCC-B group (56.2 yr) (p < 0.001), the serum alpha-fetoprotein concentrations were lower in the HCC-PB group (8.2 ng/ml) than in the HCC-B group (43 ng/ml) (p = 0.0488), and a higher familial history of liver disease was observed in the HCC-B group (p = 0.0373). However, there was no significant difference in the cumulative survival rate.

CONCLUSIONS

Positivity for anti-HBc alone is not rare compared to HBsAg(+), and the clinical features of positivity for anti-HBc alone are similar to those of HBsAg(+). Some differences in the clinical features between the two groups may be explained by differences in the time of first exposure to hepatitis B virus. Therefore, the natural course of acute hepatitis B may be reconsidered.

Authors+Show Affiliations

Saga Social Insurance Hospital, Hyogo-minami, Saga-shi, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

11808941

Citation

Yano, Yoichi, et al. "Clinical Features of Hepatocellular Carcinoma Seronegative for Both HBsAg and anti-HCV Antibody but Positive for anti-HBc Antibody in Japan." The American Journal of Gastroenterology, vol. 97, no. 1, 2002, pp. 156-61.
Yano Y, Yamashita F, Sumie S, et al. Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for anti-HBc antibody in Japan. Am J Gastroenterol. 2002;97(1):156-61.
Yano, Y., Yamashita, F., Sumie, S., Ando, E., Fukumori, K., Kiyama, M., Oyama, T., Kuroki, S., Kato, O., Yamamoto, H., Tanaka, M., & Sata, M. (2002). Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for anti-HBc antibody in Japan. The American Journal of Gastroenterology, 97(1), 156-61.
Yano Y, et al. Clinical Features of Hepatocellular Carcinoma Seronegative for Both HBsAg and anti-HCV Antibody but Positive for anti-HBc Antibody in Japan. Am J Gastroenterol. 2002;97(1):156-61. PubMed PMID: 11808941.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for anti-HBc antibody in Japan. AU - Yano,Yoichi, AU - Yamashita,Fumihiko, AU - Sumie,Shuji, AU - Ando,Eiji, AU - Fukumori,Kazuta, AU - Kiyama,Masahiro, AU - Oyama,Takashi, AU - Kuroki,Shigetaka, AU - Kato,Osamu, AU - Yamamoto,Hiroshi, AU - Tanaka,Masatoshi, AU - Sata,Michio, PY - 2002/1/26/pubmed PY - 2002/2/8/medline PY - 2002/1/26/entrez SP - 156 EP - 61 JF - The American journal of gastroenterology JO - Am. J. Gastroenterol. VL - 97 IS - 1 N2 - OBJECTIVE: We determined the prevalence of patients with hepatocellular carcinoma (HCC) who were positive for only anti-hepatitis B core (anti-HBc) antibody among 284 Japanese patients and compared their clinical features to those who were hepatitis B surface antigen positive [HBsAg(+)]. METHODS: Serum HBsAg and anti-hepatitis C virus (anti-HCV) antibody were examined for all HCC patients. Testing for anti-HBc antibody was performed in the HBsAg(-)/anti-HCV(-) patients. The clinical factors and the survival rate were compared between the HBsAg(+) patients (HCC-B) and those positive for anti-HBc alone (HCC-PB). RESULTS: There were 19 (6.7%) HBsAg(+), 236 (83.1%) anti-HCV(+), seven (2.5%) HBsAg(+)/anti-HCV(+), and 22 (7.7%) HBsAg(-)/anti-HCV(-) among the 284 patients tested. Sixteen (72.7%) of the 22 HBsAg(-)/anti-HCV(-) patients were assigned to the HCC-PB group. The prevalence of positivity for anti-HBc alone among all 284 HCC patients was 5.6%. Significant differences between the HCC-PB and HCC-B groups were that age at diagnosis was higher in the HCC-PB group (72.1 yr) than in the HCC-B group (56.2 yr) (p < 0.001), the serum alpha-fetoprotein concentrations were lower in the HCC-PB group (8.2 ng/ml) than in the HCC-B group (43 ng/ml) (p = 0.0488), and a higher familial history of liver disease was observed in the HCC-B group (p = 0.0373). However, there was no significant difference in the cumulative survival rate. CONCLUSIONS: Positivity for anti-HBc alone is not rare compared to HBsAg(+), and the clinical features of positivity for anti-HBc alone are similar to those of HBsAg(+). Some differences in the clinical features between the two groups may be explained by differences in the time of first exposure to hepatitis B virus. Therefore, the natural course of acute hepatitis B may be reconsidered. SN - 0002-9270 UR - https://www.unboundmedicine.com/medline/citation/11808941/Clinical_features_of_hepatocellular_carcinoma_seronegative_for_both_HBsAg_and_anti_HCV_antibody_but_positive_for_anti_HBc_antibody_in_Japan_ L2 - http://Insights.ovid.com/pubmed?pmid=11808941 DB - PRIME DP - Unbound Medicine ER -